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ABSTRACT
The long term prognosis of liver cancer patients remains unsatisfactory because 
of cancer recurrence after surgical interventions, particularly in patients with viral 
infections. Since hepatitis B and C viral proteins lead to inactivation of the tumor 
suppressors p53 and Retinoblastoma (Rb), we hypothesize that surgery in the context 
of p53/Rb inactivation initiate de novo tumorigenesis.
We, therefore, generated transgenic mice with hepatocyte and cholangiocyte/
liver progenitor cell (LPC)-specific deletion of p53 and Rb, by interbreeding conditional 
p53/Rb knockout mice with either Albumin-cre or Cytokeratin-19-cre transgenic mice.
We show that liver cancer develops at the necrotic injury site after surgical 
resection or radiofrequency ablation in p53/Rb deficient livers. Cancer initiation 
occurs as a result of specific migration, expansion and transformation of cytokeratin-
19+-liver (CK-19+) cells. At the injury site migrating CK-19+ cells formed small bile 
ducts and adjacent cells strongly expressed the transforming growth factor β (TGFβ). 
Isolated cytokeratin-19+ cells deficient for p53/Rb were resistant against hypoxia 
and TGFβ-mediated growth inhibition. CK-19+ specific deletion of p53/Rb verified that 
carcinomas at the injury site originates from cholangiocytes or liver progenitor cells.
These findings suggest that human liver patients with hepatitis B and C viral 
infection or with mutations for p53 and Rb are at high risk to develop tumors at the 
surgical intervention site.
INTRODUCTION
Liver cancer is one of the deadliest forms of cancer 
with approximately 700,000 deaths per year worldwide [1]. 
Hepatic resection and radiofrequency ablation (RFA) are 
the treatment of choice, especially for patients with tumors 
associated with early and severe cirrhosis respectively 
[2, 3]. However, long-term prognosis after resection or RFA 
of liver cancer remains unsatisfactory, because of the high 
recurrence rate [4, 5]. A retrospective study revealed that 
the 5-year recurrence rates after surgery (n=138) and RFA 
(n=236) were 53.7% and 69.5% respectively [6].
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Many risk factors have been associated with liver 
cancer including chronic hepatitis B and C viral infection, 
and basically all cirrhosis-inducing conditions [7]. These 
etiological exposures are believed to interfere with the cell 
cycle machinery through inactivating tumor suppressor 
pathways [8]. Among the pathways that are often disrupted 
in concert are those regulated by the tumor suppressors p53 
and Rb [9–11]. For example, viral proteins derived from 
Hepatitis B and C viruses have been shown to inactivate 
p53 as well as Rb in liver cells [12, 13]. Interestingly, liver 
specific deletion of the Rb gene in mice does not result in 
spontaneous tumor development [14], whereas deletion of all 
three pocket proteins (Rb, p107, p130) led to spontaneous 
liver cancer, indicating compensatory tumor suppressor 
mechanisms within the pocket protein family [15]. Deletion 
of p53 in mice is sufficient to cause spontaneous liver cancer 
[16, 17]. Intriguingly, liver-specific deletion of both p53 and 
Rb did not result in spontaneous liver cancer in mice aged to 
one year. However, in response to diethylnitrosamine (DEN), 
tumors started to develop at the age of three months [17, 18].
Previous studies in humans demonstrated that 
events that lead to the inhibition of the p53/Rb pathways 
occurred at early stages of the disease, indicating that 
these tumor suppressor pathways might play a critical role 
in preventing liver cancer initiation [19].
Hepatocytes, cholangiocytes and liver progenitor 
cells could function as candidates for the cell of origin in 
liver cancer [20]. However, identifying the cell of origin 
is currently not feasible in human patients. In addition, 
the lack of appropriate markers to clearly distinguish the 
differentiation stages of the different hepatic lineages 
has hindered the characterization of the cell of origin in 
human liver cancer patients [21]. In this study, we show 
that liver-specific inactivation of Rb and p53 in mice leads 
to the spontaneous formation of liver tumors at the age 
of 13 months with histological similarities to human liver 
cancers. Moreover, we show that surgical resection and 
RFA accelerate tumor genesis in p53/Rb deficient livers 
as a result of migration, expansion and transformation of 
Cytokeratin19- (CK19) positive - cells at the injury site.
RESULTS
Loss of p53 and Rb in liver results in 
spontaneous cancer
We used homologous recombination techniques 
and Cre-loxP technology to disrupt p53 and Rb function 
in the liver by crossing Alb-cre to p53f/f;Rbf/f mice 
(Supplementary Figure S1A and S1B).
Homozygous deletion of p53 and Rb in the liver led 
to spontaneous tumor formation in 13-26 month-old mice 
with an incidence of 63% (n=19) (Figure 1A; Table 1 ). No 
liver tumors were observed in age-matched control mice 
(n=17). Analysis of tumors discovered different phenotypes 
including well-differentiated hepatocellular carcinoma (HCC, 
Figure 1B), cholangiocarcinomas (CC, Figure 1C) and 
undifferentiated hepatocholangiocellular carcinomas HCC/
CC (Figure 1D). Importantly undifferentiated carcinomas 
contained multiple areas with coagulation necrosis (Figure 
1E) accompanied by infiltration of inflammatory cells (Figure 
1D, Supplementary Figure S1C). The degree of necrosis and 
inflammation was more severe in undifferentiated HCC/CC 
compared to differentiated HCC/CC (Figure 1E). Notably 
the liver surrounding undifferentiated tumors displayed also 
more infiltration of inflammatory cells compared to well-
differentiated tumors (Figure 1F). These findings suggest that 
loss of epithelial differentiation is a consequence of tissue 
injury and its associated inflammatory response. Alternatively, 
since undifferentiated carcinomas exhibited more necrosis this 
might trigger an enhanced immune response.
Hepatic resection leads to cancer at the ligation 
site in p53Δ/Δ;RbΔ/Δ livers.
Survival analysis demonstrated that the mean life span 
of Alb-cre+/-;p53Δ/Δ;RbΔ/Δ mice that developed spontaneous liver 
tumors (527 days; n=12) was significantly shorter than control 
Alb-cre-/-;p53f/f;Rbf/f mice (730 days; n=17; P=<0.05) (Figure 
2A; Table 1 ). Although deletion of p53 and Rb is already 
induced during fetal development [22], tumor formation 
occurred relatively late in life, indicating that additional events 
are required to initiate cancer. To investigate whether tumor 
development could be accelerated in p53Δ/Δ;RbΔ/Δ liver, we 
performed two subsequent partial hepatectomies (PH). Surgical 
resection resulted in early formation of large liver tumors with 
an incidence of 66% (Table 1). The mean survival time of Alb-
cre+/-;p53Δ/Δ;RbΔ/Δ mice that underwent surgery and developed 
liver tumors was significantly shorter compared to tumor mice 
without surgery (Figure 2A; Table 1 ). We expected that liver 
tumors would be located in the regenerating lobes, because 
these lobes underwent multiple rounds of cell division, which 
would likely increase the risk of gaining additional mutations. 
Surprisingly, in all p53Δ/Δ;RbΔ/Δ livers a large tumor was found 
at the stump of the resected lobes (Figure 2B), whereas in the 
regenerating lobes hardly any liver tumors were detected. 
Histological examination revealed that all tumors located at 
surgical sites were undifferentiated HCC/CC accompanied 
with multifocal necrosis and infiltration of inflammatory cells 
(Figure 2C, Table 1). Tumors that developed occasionally 
in a regenerated lobe away from the injury site were more 
well-differentiated HCC or CC (Figure 2D, 2E; Table 1 ). 
PH on control mice did not cause liver cancer (Supplementary 
Figure S2).
RFA initiates cancer at the necrotic injury site of 
p53Δ/Δ;RbΔ/Δ livers
We evaluated whether RFA, a different therapy 
approach to remove tumors from the liver, had any effects 
on p53Δ/Δ;RbΔ/Δ and control p53f/f;Rbf/f livers. Mice were 
euthanized weekly for post RFA analysis from 1-10 weeks 
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(Supplementary Figure S3A). Examination of the injured 
liver lobes revealed that distinct neoplastic foci were 
detectable within the necrotic regions of p53Δ/Δ;RbΔ/Δ and 
not in control livers from 5 weeks after RFA (Figure 3, 
Table 1 ). Tumors that developed upon RFA treatment 
were similar to tumor induced by PH and were classified 
as undifferentiated HCC/CC (Figure 3 and 2B, 2C; Table 
1 ). In Alb-cre+/-;p53Δ/Δ , 4/5 mice developed tumors 
within 6 months, whereas no tumor was observed in Alb-
cre+/-;RbΔ/Δ mice within 12 months after RFA treatment. 
Morphologically, tumors observed in p53Δ/Δ liver were 
identical to p53Δ/Δ;RbΔ/Δ tumors (data not shown).
CK19+ cells migrate, expand and transform 
within necrotic regions of p53Δ/Δ;RbΔ/Δ livers
Next we investigated which cell types invaded 
into the necrotic region before distinct neoplastic foci 
were recognizable. One week after RFA, we observed 
in p53Δ/Δ;RbΔ/Δ and in control livers that multiple well 
differentiated bile ducts were present within the necrotic 
region (Figure 3). These bile ducts were surrounded by 
myofibroblasts, inflammatory cells and endothelial cells 
and localized adjacent to the border between dead and 
viable liver tissue. Intriguingly, at 3 weeks these bile ducts 
and the surrounding cells had migrated and expanded 
deeper into the necrotic liver regions in p53Δ/Δ;RbΔ/Δ and 
not in control liver. Notably, viable well-differentiated 
hepatocytes had never been detected within necrotic 
regions (Supplementary Figure S3B). Presence and 
expansion of bile ducts within the necrotic region was 
confirmed by immunostaining for CK19, a marker for 
cholangiocytes and liver progenitor cells (LPC) (Figure 
4A). Number of bile ducts (Figure 4B) and proliferation 
index of cholangiocytes (Figure 4C & 4D) in p53Δ/Δ;RbΔ/Δ 
liver were increased 3 weeks after RFA. These findings 
suggest that liver-specific loss of p53 and Rb results in 
enhanced migration and proliferation of bile ducts into the 
area of tissue injury. Remarkably, 5-6 weeks post RFA and 
at later time points, bile duct structures were still present 
Figure 1: Liver specific loss of p53 and Rb in mice results in spontaneous liver tumors. A. Insitu view of a liver tumor in 
the abdomen of Alb-cre+/-; p53Δ/Δ; RbΔ/Δ mouse, B. well differentiated HCC, C. well differentiated CC, D. undifferentiated HCC/CC with 
inflammation and necrosis(N). Dotted lines indicate borders between tumor T. and normal liver (L). Histological images are magnified 
100x. Quantification of inflammation and necrosis; E. in well differentiated and undifferentiated HCC/CC and F. in non-tumor liver tissues 
adjacent to neoplastic tissues. Data represent average ± s.e.m, (n= 10). *p <0.05, undifferentiated versus well differentiated HCC/CC.
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within the neoplastic foci surrounded by inflammatory 
cells, but were smaller in size (Figure 3).
The Alb-cre transgene is known to specifically 
express Cre in hepatocytes. To verify that homologous 
recombination of conditional alleles had also occurred 
in cholangiocytes/LPC and not in hepatocytes only, we 
crossed Alb-cre+/-;p53Δ/Δ;RbΔ/Δ mice with mice carrying 
the LacZ-Cre-reporter (LSLR26Rf/f) [23]. As expected 
LacZ expression was detected in viable hepatocytes of 
Alb-cre+/™; LSLR26RΔ/Δ mice (Figure 4E). Importantly, bile 
ducts in non-injured livers (Supplementary Figure S1B) 
and bile ducts invading early into the necrotic regions of 
Alb-cre+/-;p53Δ/Δ;RbΔ/Δ;LSLR26RΔ/Δ mice showed strong 
LacZ expression (Figure 4E), indicating that p53 and 
Rb has not only been deleted in hepatocytes but also in 
cholangiocytes/LPC. LacZ expression was also observed 
in liver tumors 10 weeks after RFA, and we found that 
undifferentiated carcinomas cells and cholangiocytes/
LPC expressed LacZ, supporting that undifferentiated 
neoplastic cells originate from epithelial liver cells (Figure 
4F). Deletion of p53 and Rb in liver tumors was confirmed 
by PCR analysis (Supplementary Figure S1A).
p53Δ/Δ;RbΔ/Δ CK19+ cells are resistant to TGFβ 
and hypoxia mediated growth inhibition
Since the proliferation rate of wild type 
cholangiocytes within the RFA zone decreased from 
1 to 3 weeks (Figure 4C, 4D) while p53/Rb deficient 
cholangiocytes continue to proliferate at high rate, we 
hypothesize that p53Δ/Δ; RbΔ/Δ cholangiocytes might be 
less responsive towards inhibitory proliferation signals, 
such as the transforming growth factor beta (TGFβ). 
TGFβ is a secreted protein and a known inhibitor of 
cellular proliferation [24, 25]. We found that TGFβ is 
highly expressed by cells surrounding the migrating 
cholangiocytes at the RFA site 3 weeks after surgery 
(Figure 5A). To test our hypothesis, we isolated and 
cultured cholangiocytes/LPC from p53Δ/Δ;RbΔ/Δ and wild 
type livers using organoid technology (Figure 5B) [26]. 
Administration of TGFβ to the culture medium of wild 
type organoids strongly reduced the DNA replication rate, 
quantified by EdU incorporation (Figure 5C). In contrast, 
TGFβ addition to p53Δ/Δ;RbΔ/Δ organoids resulted in less 
inhibition of DNA replication (Figure 5C). Time course 
analysis with daily measurements of DNA replication 
further supported that p53Δ/Δ;RbΔ/Δ organoids were less 
sensitive to inhibitory effects and displayed a higher 
proliferation rate in response to TGFβ (Figure 5D). 
Similar responses were observed when CK-19+ organoids 
were cultured under hypoxic conditions. Hypoxia 
decreased the proliferation rate and viability of wild type 
liver organoids, whereas p53Δ/Δ;RbΔ/Δ organoids show no 
reduction in proliferation and viability (Figure 5E, 5F). 
To investigate whether oxidative stress contributes to 
the positive selection of CK19+ cells after RFA [27], we 
exposed organoids to hydrogen peroxide or we removed 
the anti-oxidant N-Acetyl-Cysteine (NAC) from the 
organoid medium. In contrast to hypoxia and TGFβ, wild 
type and p53Δ/Δ;RbΔ/Δ organoids did not differ significantly 
in response to oxidative stress (Supplementary Figure 
S9A-S9D). Next, we evaluated the angiogenesis response 
Table 1: Life span, tumor incidence and tumor differentiation of mice with the indicated genotypes and 
types of surgical interventions
Mean life span Tumor at 
surgery site












527* n.a. n.a. 63% (12/19) 66% (8/12)***
3 Alb-cre
+/-;p53Δ/Δ;RbΔ/Δ 
(PH) 229** 66% (23/35) 100% (23/23) 6% (2/35) 0% (0/2)
4 Alb-cre
+/-;p53Δ/Δ;RbΔ/Δ 
(RFA) n.a. 100% (16/16) 100% (16/16) 0% (0/16) n.a.
5 Ck19-cre
+/-;p53Δ/Δ;RbΔ/Δ 
(RFA) n.a. 42% (10/24) 100% (10/10) 0% (0/24) n.a.
Group 2 has a significant lower mean life span compared to group 1 (*P<0.05); group 3 has a significant lower mean life 
span compared to group 2 (**P< 0.001; SPSS log rank test). Epithelial-mesenchymal transition (EMT) in tumors located 
at surgery site of group 3 is significantly higher compared to tumors of group 2 (***P<0.01; two sided students t-test). PH, 
partial hepatectomy; RFA, radiofrequency ablation; n.a., not applicable.
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towards the injury. However the number of blood 
vessels at the transition zone two weeks after RFA did 
not differ between control and p53/Rb deficient livers 
(Supplementary Figure S10A-S10B). Furthermore, the 
analysis of the polyploidy status of isolated wild type and 
p53/Rb deficient CK19+ cells from livers, revealed no 
difference in polyploidy between the two genetic groups 
(Supplementary Figure S11).
Tissue destruction leads to epithelial-
mesenchymal transition (EMT) of p53Δ/Δ;RbΔ/Δ 
neoplastic liver cells
Analysis of all spontaneous tumors arising in p53Δ/Δ;RbΔ/Δ 
livers revealed that approximately 30% of tumors were 
well differentiated HCC or CC, while the remaining 
tumors were either poorly differentiated or undifferentiated 
(Figure 6A). Reduced differentiation of spontaneous 
tumors was associated with the presence of prominent 
necrotic foci and strong invasion of inflammatory cells 
(Figure 1E). Consistent with these observations, 100% 
of the liver tumors that developed after PH or RFA were 
undifferentiated HCC/CC (Figure 6A; Table 1 ). These 
findings prompt us to hypothesize that tissue destruction 
induced EMT of neoplastic liver cells. Selected markers 
were used to investigate the differentiation degree of the 
liver tumors in more detail. Hepatocyte nuclear factor 4 
alpha (HNF4α), a nuclear marker for mature hepatocytes 
[28], was strongly expressed in normal hepatocytes 
and well differentiated HCC, whereas undifferentiated 
carcinomas showed almost no expression (Figure 6B). We 
observed that bile ducts located within undifferentiated 
carcinoma showed weak expression of HNF4α, which is 
in line with previous studies describing HNF4α expression 
in activated bile ducts (Figure 6B) [28]. CK19 staining 
displayed strong expression in normal bile ducts, in 
well differentiated CC, and in large and small ductular 
structures within undifferentiated carcinomas (Figure 4F, 
6B, data not shown). Undifferentiated carcinoma cells 
showed infrequent low expression of CK19 (Figure 4F, 
6B). Next, we investigated the expression of E-cadherin, 
a general marker for epithelial cells. Strong membranous 
Figure 2: Hepatic resection in Alb-cre+/-; p53Δ/Δ; RbΔ/Δ mice results in reduced survival and undifferentiated carcinomas 
at the ligation site. A. Survival curves of Alb-cre+/-;p53Δ/Δ;RbΔ/Δ mice developing liver tumors after (+PH; red) or without (-PH; black) 
partial hepatectomy. Life span of control mice is indicated by dotted line. B. View of a liver tumor after PH. C. H&E (100x) stained liver 
from undifferentiated carcinomas within the remaining stump (ST). Suture material (arrowheads) localized in neoplastic lesions. D. Well 
differentiated HCC and E. CC with moderately differentiated bile ducts (arrows) in regenerating lobes (RL). Dotted lines separate normal 
liver (L) and tumor (T).
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E-cadherin expression was observed in normal hepatocytes 
and cholangiocytes, in well differentiated HCC and CC, 
and in ducts of undifferentiated carcinomas. Consistent 
with the expression pattern of the other epithelial marker 
HNF4α and CK19, undifferentiated carcinoma cells lacked 
E-cadherin expression (Figure 6B and Supplementary 
Figure S4). To determine whether these carcinomas cells 
had gained a mesenchymal phenotype, we performed 
S100A4 staining. Undifferentiated carcinomas cells 
show strong S100A4 expression, whereas bile ducts 
and hepatocytes lacked S100A4 expression (Figure 6B 
and Supplementary Figure S4). We also observed co-
localization of CK19 and S100A4 as well as CK19 and 
vimentin in early tumor lesions (Supplementary Figure 
S5A, S5B). Other regions of advanced tumor lesions 
and normal liver tissues did not show co-expression of 
epithelial and mesenchymal markers (Supplementary 
Figure S6A, S6B).
Finally, Ki67 staining demonstrated enhanced Ki67 
expression in undifferentiated carcinomas (Supplementary 
Figure S6C). Together these data suggest that tissue 
destruction by surgical resection or RFA leads to epithelial-
mesenchymal transition and enhanced proliferation of 
p53Δ/Δ; RbΔ/Δ neoplastic cholangiocytes/LPC.
Figure 3: RFA in Alb-cre+/-; p53Δ/Δ; RbΔ/Δ mice leads to expansion of bile duct cells and formation of liver tumors at 
the injury site. Representative H&E liver sections from necrotic lesions of Alb-cre+/-; p53Δ/Δ; RbΔ/Δ mice and control Alb-cre-/-;p53f/f;Rbf/f 
mice at different time points after RFA. Migration of bile ducts (arrows) and appearance of liver tumors (T). Dotted lines mark the border 
between liver (L) and necrotic RFA lesion (N). Left and middle panel 100x; right panel 200x.
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Anti-inflammatory drugs could not prevent 
tumor development at the RFA injury site
Because the initiation of liver tumors at the injury 
site is associated with infiltration of inflammatory 
cells (Figure 3), we investigated whether inflammation 
contributes to tumor development. One group of Alb-cre+/-
;p53Δ/Δ;RbΔ/Δ mice received Sulindac in drinking water 
and control group received plain water. A second cohort 
group received Dexamethasone or saline a day before 
RFA and continued treatment for 9 weeks. The Sulindac 
treated group (n=6) did not differ from the control 
group. Dexamethasone treated mice revealed reduced 
inflammation and bile ducts migration into necrotic 
Figure 4: Loss of p53 and Rb leads to enhanced proliferation cholangiocytes within the RFA site. A. CK19 positive and 
B. quantification of bile ducts. C. Ki67-positive cholangiocytes and D. quantification of Ki67 positive cholangiocytes. [(A), (C)] Images 
magnified 200x. Histograms represent average ± s.d. of five fields at 20x, (n= 2-4), *p <0.05 versus control. E. x-gal, and expansion of p53/
Rb-deficient bile ducts (arrows). Upper panel 100x, lower panel 200x. F. X-gal and CK19 staining 10 weeks after RFA. Bile ducts (arrows) 
within the tumors (T), left panel 40x, right panel 200x. Viable liver (L) and necrotic (N) tissue.
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Figure 5: p53 and Rb deficient bile ducts are resistant to proliferation inhibitory signals induced by TGFβ1 and hypoxia. A. 
TGFβ1 expression in liver (L) and necrotic tissue (N), 3 weeks after RFA. Magnifications: 200x (top row) and 400x (bottom row). B. H&E (top 
row) and CK19 (bottom row) on bile duct organoids of indicated genotypes, all images at 200x magnification. C. Proliferation of organoids from 
wild type and p53/ Rb deficient livers at an increasing dosage of TGFβ1. D. Comparison of proliferation rate of wild type versus p53/Rb knockout 
organoids cultured for 5 days with and without TGFβ1 treatment. E. Proliferation rate of control versus p53/ Rb deficient organoids under normoxia 
and 2.5% hypoxia for 24 hours. F. Survival score of organoids under normoxic and hypoxic conditions shown by trypan blue exclusion in control 
versus p53/ Rb deficient organoids. Histograms represent mean and standard deviations, *p < 0.05, wild type versus p53/Rb deficient cells.
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region, three weeks after RFA (Supplementary Figure 
S7). Surprisingly only one mouse of the dexamethasone 
treated group did not develop tumors at RFA site, 75% 
(6/8) developed smaller tumors compared to control and 
one mouse developed a tumor larger than the control mice. 
As expected, all saline treated mice developed tumors at 
RFA site. Treatment with high dose of Dexamethasone 
(4mg/kg) alone did not induce any pathological change 
Figure 6: Surgical resection or RFA in Alb-cre+/-; p53Δ/Δ; RbΔ/Δ mice lead to formation of undifferentiated carcinomas that 
underwent epithelial-mesenchymal transition. A. Classification of spontaneous liver tumors (-PH), tumor associated with partial 
hepatectomy (+PH) or radiofrequency ablation (+RFA), and number of tumors analyzed (n). B. Images of H&E (20x), hepatocyte nuclear factor 
4α (HNF4α, 100x), CK19 (100x), E-cadherin (100x), and S100A4 (40x) and magnifications for the respective images are shown in brackets.
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in the liver (data not shown). These findings suggest that 
reducing the inflammatory response at the injury site does 
not significantly contribute to the development of liver 
tumors after RFA.
CK19-specific deletion of p53 and Rb leads to 
liver cancer after RFA
Given the migration and expansion of 
cholangiocytes into early necrotic lesions of p53Δ/Δ;RbΔ/Δ 
livers (Figure 3), we examined whether the bile duct cell/
LPC could represent the cell-of-origin in this injury-
induced mouse model of liver cancer. To delete p53 and 
Rb specifically in cholangiocytes/LPC, we bred mice 
transgenic for Cre under the control of the tamoxifen-
inducible CK19 promoter (CK19-creERT) [29] with 
p53f/f;Rbf/f mice. To monitor Cre-specific expression, 
mice were also crossed with the R26LSL-lacZ reporter 
mice. 5-bromo-4-4chloro-3-indolyl-D-galacto-pyrmoside 
(X-gal) staining on liver sections from CK19-cre+/-
;p53Δ/Δ;RbΔ/Δ;LSLR26RΔ/Δ mice injected with tamoxifen 
demonstrated LacZ expression in cholangiocytes, not in 
hepatocytes or stromal cells (Figure 7A). To further ensure 
that CK19-cre expression is limited to cholangiocytes/
LPC, we exposed tamoxifen-injected CK19-cre+/-;p53Δ/
Δ;RbΔ/Δ;LSLR26RΔ/Δ mice to a 3,5-diethoxycarbonyl-1,4-
dihydrocollidine (DDC) diet for three weeks to induce 
proliferation of cholangiocytes/LPC [30]. We observed 
LacZ expression only in cholangiocytes/LPC during 
DDC exposure and after switching back to a normal diet 
(Supplementary Figure S8A). These findings are in line 
with previously published findings which demonstrate 
that CK19-cre expressing cells are not able to generate 
hepatocytes even under stress conditions [31]
Importantly, RFA resulted in the formation of 
liver tumors at the site of tissue destruction in 42% of 
CK19-cre+/-;p53Δ/Δ;RbΔ/Δ (Figure 7A; Table 1 ). Distinct 
neoplastic foci were detectable at first 9 weeks after RFA 
treatment and tumors showed strong LacZ expression and 
PCR analysis confirmed deletion of p53 and Rb within 
these tumors (Figure 7A and Supplementary Figure 
S1A). Comparative histological analysis revealed that the 
tumors had the same morphology and expression pattern 
of epithelial and mesenchymal markers similar to tumors 
that developed in Alb-cre+/-;p53Δ/Δ;RbΔ/Δ mice after PH or 
RFA (Figure 7B, and Supplementary Figure S8B). These 
findings provide strong evidence that the bile duct cell/
LPC is the cell-of-origin of p53Δ/Δ;RbΔ/Δ liver tumors 
induced by tissue destruction.
DISCUSSION
An important question, which is difficult to address 
in human patients, is whether liver cancers originate from 
hepatocytes, liver progenitor cells or cholangiocytes. We 
used genetically modified mice that lack the expression 
of tumor suppressors in different liver cell lineages to 
identify the cell of origin in an injury-induced model 
of liver cancer. Albumin-cre activation in p53/Rb 
conditional knockout mice resulted in the expansion of 
structures with characteristics of bile ducts. We showed 
that Albumin-cre transgenic mice expresses cre not only 
in hepatocytes, but also in cholangiocytes/LPC. It is also 
possible that liver tumors originated from dedifferentiated 
hepatocytes in Albumin-cre transgenic mice, as it has been 
shown previously [32]. To genetically delete Rb and p53 
exclusively in cholangiocytes/LPC we used the Ck19-
creERT transgenic mice [29] and found that the same 
type of tumors developed at the same location. We and 
others have never observed any Ck19-cre expression in 
hepatocytes not even after DDC exposure (Supplementary 
Figure S8A, [31], indicating that CK19-cre expressing 
cells in this transgenic mouse line do not generate 
hepatocytes and also do not originate from dedifferentiated 
hepatocytes. These observations strongly suggest that p53/
Rb deficient liver tumors in CK19-cre expressing mice 
originate from cholangiocytes/LPC at the injury site.
This study provides insights into the pathogenesis 
of the development of liver tumors after surgical resection 
or RFA treatment, a scenario that is often observed in 
human liver cancer patients that underwent surgical or 
RFA therapy [6]. We provide now strong evidence that 
the necrotic injury site induced by these therapeutic 
modalities could serves as an optimal microenvironment 
for the initiation of liver tumors. Notably, surgical 
resection and RFA caused liver cancer only in p53 and 
Rb deficient livers, while wild type mice that underwent 
similar procedure were tumor-free. Nevertheless, p53 and 
Rb are commonly inactivated in human liver cells for 
example through infection with hepatitis B and C virus 
[33–35], raising the risk to develop liver tumors after 
surgical interventions. In fact, a recent study showed 
that liver cancer patients (n=266) infected with Hepatitis 
B virus had a 2-year recurrence rate of 54.3% after RFA 
[36]. Furthermore a study with 72 HCC patients revealed 
that a high hepatitis B virus load (>2000IU/ml) at the 
time of tumor resection was the most important risk 
factor for HCC recurrence after 19 months (p=0.001) 
[34] . Moreover antiviral treatment after resection was 
associated with significantly lower cumulative risk of 
recurrence [36, 37].
We show that thermal destruction leads to massive 
coagulation necrosis, followed by a wound healing 
response characterized by the migration of activated 
cholangiocytes/LPC, inflammatory cells, myofibroblasts, 
and deposition of extracellular matrix (fibrosis) into the 
necrotic regions. In wild type livers this dynamic wound 
healing process slows down and results in sequestration of 
the necrotic regions. In contrast, the chronic inflammatory 
response continues in p53/Rb deficient livers and 
leads to further expansion and enhanced proliferation 
of cholangiocytes. Remarkably, within 5 weeks after 
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injury, cholangiocytes/LPC transform and initiate tumor 
formation within the necrotic regions. These migrating 
and expanding bile ducts were surrounded by cells that 
expressed high levels of TGFβ. Based on the morphology 
and the presence of brown pigment in the cytoplasm, the 
TGFβ-expressing cells represent most likely macrophages 
that were possibly recruited to injury site to phagocytize 
the necrotic debris (Figure 5A). Previous studies have 
shown that an increased TGFβ gradient promotes 
differentiation towards biliary lineage [16, 17, 25, 38] 
which is consistent with our finding that we only observed 
migration and expansion of cholangiocytes, and never 
observed any hepatocytes in the necrotic region. When 
we exposed isolated cholangiocytes/LPC to different 
dosages of TGFβ, we observed that Rb/p53 deficient 
cells proliferate more efficiently than wild type cells. 
These findings are also in line with the observation that 
the TGFβ-receptor contributes to the development of liver 
tumors in p53 deficient livers [16]. In addition, TGFβ 
is well known for inducing EMT in cancer cells [39], a 
phenotype that we clearly observed in the tumors that 
developed at necrotic injury where many cells express 
high levels of TGFβ. Together, our studies provide strong 
evidence for a model in which the increased TGF-β 
Figure 7: Cholangiocyte specific deletion of p53 and Rb in mice leads to undifferentiated carcinomas at the RFA injury 
site. A. Left panel: in situ x-gal positive bile ducts cells (BD, arrows) at 400x magnification in normal liver (L): portal fibroblasts, blood 
vessels (BV) and hepatocytes were not stained. Right panel: x-gal positive liver tumor at RFA injury site (20x). B. HNF4α and CK19 in liver 
and tumors. The presence of bile ducts (arrows) within the tumors is indicated. Dotted lines separates normal liver tissue (L) and tumors 
(T). Left panel, 100x, right panel 400x.
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gradient generated by macrophages at the necrotic injury 
site promotes the migration, expansion, transformation 
and EMT of p53 and Rb deficient cholangiocytes/LPC.
Surprisingly, the use of anti-inflammatory agents 
showed that the overall tumor incidence after RFA was 
not significantly reduced, suggesting that other mechanism 
such as hypoxia may contribute to peri-necrotic tumor 
formation. Our in vitro study with CK19+ isolated cells 
(Figure 5E and Supplementary Figure S9A, S9B) as 
well as our previous studies utilizing an in vivo colon 
carcinoma cancer model [40] provide strong evidence that 
hypoxia could contribute to the positive selection cancer 
cells at the injury site.
In summary, our findings show that deletion of 
p53 or Rb leads to the expansion, transformation, and 
EMT of bile duct cells/LPC within an inflammatory, 
hypoxic and necrotic environment induced by surgery/
RFA. We conclude that the combination of loss of 
tumor suppressors, creation of hypoxia/necrosis and the 
accompanied activation of TGFβ signaling causes cancer 
and EMT at the surgery site.
Finally, we provide the field with a novel mouse 
model, in which surgical resection and RFA treatment 
leads to formation of highly aggressive, fast growing and 
undifferentiated carcinomas. This model could represent a 
tool to test the efficacy of anti-cancer drugs that are aimed 
to use in human patients that developed liver tumors after 
hepatic resection or RFA.
MATERIALS AND METHODS
Animals and histology
All experiments were approved by the Utrecht 
University Animal Ethics Committee and performed 
according to institutional and national guidelines. 
Albumin-cre and R26R-LacZf/f mice were derived from 
Jackson laboratory [22, 23]. Rbf/f and p53f/f mice were 
provided by Dr. A. Berns (Netherlands Cancer Institute, 
Amsterdam, The Netherlands). Ck19-cre-ERT mice 
were generated as described previously [22]. Partial 
hepatectomy (PH) and RFA experiments were performed 
on mice aged for 10-14 weeks. First PH was done as 
described previously [41]. The second PH, removing the 
right lateral lobe, was performed 10 weeks after the first 
PH [42]. RFA was performed as described previously 
[40]. X-gal and immunostaining on liver sections were 
performed as described previously [43].
Additional description of materials and methods is 
provided as supplementary information .
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